title: Risks and benefits of (pharmaco)epidemiology.
abstract: Pharmacoepidemiology is a relatively young scientific discipline that has seen tremendous growth in interest over the past two decades. This is partly due to changes in the approval of new drugs, which often now require proactive studies to monitor and extend the knowledge of safety in the postauthorization period. Pharmacoepidemiology studies are observational in nature, in contrast to the randomized controlled trial which is the mainstay of drug development. This means that such studies need careful design and execution in order to maximize the benefits of proactive research in the 'real-life' clinical environment and minimize the risks of false results.
authors.affiliation: Takeda Global Research and Development (Europe), 61 Aldwych, London WC2B 4AE, UK.
authors.forename: Lesley
authors.initials: L
authors.lastname: Wise
keywords: benefit; bias; confounding; pharmaceutical; pharmacoepidemiology; postauthorization; risk
references.citation: Stat Med. 2006 May 30;25(10):1768-97
references.pmid: 16220518
references.citation: Curr Med Res Opin. 2008 Jul;24(7):1861-8
references.pmid: 18507892
references.citation: Nat Rev Drug Discov. 2009 Oct;8(10):779-82
references.pmid: 19763106
references.citation: Lancet. 2004 May 22;363(9422):1728-31
references.pmid: 15158638
references.citation: N Engl J Med. 2008 May 29;358(22):2319-31
references.pmid: 18480196
references.citation: BMJ. 2009 Oct 01;339:b3805
references.pmid: 19797344
references.citation: Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):850-3
references.pmid: 17636552
references.citation: Stat Med. 1998 Oct 15;17(19):2265-81
references.pmid: 9802183
references.citation: BMJ. 2004 Jul 3;329(7456):2-3
references.pmid: 15231587